Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

5 Wall Street analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $11.00 to $14.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH shares have increased by 138.7% and is now trading at $10.31.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Tuesday, February, 28th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.08. The biotechnology company had revenue of $28.40 million for the quarter, compared to analysts' expectations of $28.82 million. Aurinia Pharmaceuticals had a negative net margin of 80.71% and a negative trailing twelve-month return on equity of 25.44%. The company's revenue was up 21.4% on a year-over-year basis. During the same period in the previous year, the business earned ($0.25) EPS.

ETFs with the largest weight of Aurinia Pharmaceuticals (NASDAQ:AUPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), ProShares Ultra Nasdaq Biotechnology (BIB).

Aurinia Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Friday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28.40 million-$28.40 million, compared to the consensus revenue estimate of $26.97 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Armistice Capital LLC (3.52%), Point72 Asset Management L.P. (1.54%), Renaissance Technologies LLC (1.16%), Morgan Stanley (1.05%), Geode Capital Management LLC (0.88%) and Natixis (0.69%). Insiders that own company stock include George M Milne Jr, Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $10.31.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.47 billion and generates $134.03 million in revenue each year. The biotechnology company earns $-108,180,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis.

The company employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.